SCHEMBL4883339

SCHEMBL4883339

CCc1ccc(C(=O)/C=N/O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
PLK1 P53350 1/20 0.48
MAPT P10636 3/20 0.45
HTT P42858 2/20 0.45
RAB9A P51151 1/20 0.45
MAOB P27338 1/20 0.45
THRB P10828 5/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 3/20 0.42
THRA P10827 4/20 0.42
TDP1 Q9NUW8 2/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
ALOX12 P18054 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4883345 1.00 ALDH1A1 (0.53) ALDH1A1PLK1MAPTHTTRAB9A
SCHEMBL28098954 0.80 FAAH (0.62) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL4411591 0.80 CA1 (0.58) ALDH1A1MAPTHTTRAB9ASMN1; SMN2
SCHEMBL4411590 0.80 CA1 (0.58) ALDH1A1MAPTHTTRAB9ASMN1; SMN2
SCHEMBL5464457 0.78 ALDH1A1 (0.61) ALDH1A1MAPTHTTRAB9AMAOB
SCHEMBL11436643 0.78 ALDH1A1 (0.61) ALDH1A1MAPTHTTRAB9AMAOB
SCHEMBL28863719 0.78 KMT2A (0.36) ALDH1A1MAPTHTTRAB9ATHRB
SCHEMBL1483694 0.78 ALDH1A1 (0.59) ALDH1A1PLK1MAPTHTTRAB9A
SCHEMBL8383928 0.77 ALDH1A1 (0.44) ALDH1A1PLK1MAPTSMN1; SMN2LMNA
SCHEMBL8383927 0.77 ALDH1A1 (0.44) ALDH1A1PLK1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227787-A1 Use of New Lipoxygenase Inhibitors BIOLIPOX AB (SE) 2008-09-18 US disclosed
EP-1725227-A1 USE OF NEW LIPOXYGENASE INHIBITORS Biolipox AB (SE) 2006-11-29 EP disclosed
WO-2005084656-A1 USE OF NEW LIPOXYGENASE INHIBITORS BIOLIPOX AB (SE) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227787-A1 Use of New Lipoxygenase Inhibitors ALOX15, ALOX15B, ALOX12 ALDH1A1 464/4885PLK1 4503/4885MAPT 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.